Search results
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Morningstar· 1 week agoBoehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned. R&D investments were substantial, at 22.5% of net sales.